EXIAR and NPF Materia Medica Holding continue to cooperate in supplying pharmaceutical products
EXIAR JSC and NPF Materia Medica Holding LLC signed a new short-term receivables insurance contract for 2020-2021. It was decided to increase the cover by 40% to $10M.
“The domestic pharmaceutical industry has fairly high export potential, but the volume of foreign supplies of Russian products lags far behind that of the leading pharmaceutical distributors. We are interested in providing comprehensive support to Russian companies that manufacture effective medicines and vaccines and possess promising developments in innovative drugs. One of our partners, NPF Materia Medica Holding LLC, is the largest local pharmaceutical company, to whom we provide short-term receivables insurance services continuously since 2017. This year we have almost doubled the insurance coverage. We hope to strengthen our cooperation in the future,” Nikita Gusakov, General Director of EXIAR JSC.
“Our medicines are widely known both in Russia and abroad. Today we continue to strengthen our positions by expanding production facilities and approaching new markets. We export about 20% of our products to 17 countries worldwide, including the CIS countries and Southeast Asia. We are a national pharmaceutical leader in exporting OTC medicines. Cooperation with EXIAR JSC, our committed partner, contributes a lot to the achievement of our ambitious goals,” Pavel Baskakov, General Director of NPF Materia Medica Holding LLC.
NPF Materia Medica Holding LLC is one of the largest Russian pharmaceutical companies, which is engaged in the development, production and promotion of proprietary innovative OTC medicines, covering the most sought-after therapeutic areas, including antiviral, neurological, gastroenterological, men's health and other medicines. The most known of them are Ergoferon, Anaferon, Renalgin, Tenoten, Divaza, Afalaza, Impaza, Subetta, etc.